Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Shenzhen YHLO Biotech Co., Ltd.

Shenzhen YHLO Biotech Co., Ltd. (YHLO) is an immunoassay solutions company that specializes in developing, manufactur... read more Featured Products: More products

Download Mobile App




Serum-IgG Responses in Patients with Mild and Severe COVID-19

By LabMedica International staff writers
Posted on 04 Nov 2020
The coronavirus disease 2019 (COVID-19) pandemic continues, causing considerable morbidity and mortality worldwide. The severity of COVID-19 ranges from asymptomatic to fatal pneumonitis, with mildly symptomatic patients accounting for approximately 80% of all cases according to current understanding.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, gains entry to human cells by binding the angiotensin-converting enzyme 2 (ACE2) receptor with the receptor-binding domain (RBD) of its spike (S) protein. Antibodies targeting the S-protein may effectively neutralize the virus.

Microbiologists and Immunologists at the University of Gothenburg (Gothenburg, Sweden) recruited a cohort of 47 patients between February 25th and March 25th 2020. All patients had been diagnosed with SARS-CoV-2 with RT-PCR that was performed in a QuantStudio 6 instrument (Applied Biosystems, Foster City, CA, USA). Serum-IgG antibodies against SARS-CoV-2 were analyzed using two commercially available serological assays: the qualitative Architect chemiluminescent microparticle immunoassay (Abbott Laboratories, Abbott Park, IL, USA), measuring IgG against SARS-CoV-2 N-protein, and the quantitative iFlash 1800 chemiluminescent immunoassay (Shenzhen YHLO Biotech Co, LTD, Shenzhen, P.R.China), which measures IgG against both SARS-CoV-2 S- and N-proteins. Neutralizing antibodies (NAb) were determined after inactivation of the complement in serum.

The scientists reported that that all patients with severe symptoms and 29 (90.6%) patients with mild symptoms of COVID-19 developed SARS-CoV-2-specific IgG antibodies in serum. The time to seroconversion was observed to be significantly shorter in patients with severe symptoms compared to mild symptoms (median, 11 versus 22 days). Further, they found significantly higher concentrations of IgG antibodies in patients with severe symptoms (mean 107 AU/mL) than in patients with mild symptoms (mean 65 AU/mL) within 35 days post symptom onset.

Meanwhile, among patients with mild symptoms, three (9.4%) did not develop detectable IgG antibodies as determined using the commercially available assays during the follow-up period, 91–105 days post symptom onset. To further investigate the humoral immune response against SARS-CoV-2 in these three patients, the team analyzed neutralizing antibodies in serum samples collected 78–91 days post symptom onset. All three patients were found to have detectable virus-neutralizing antibodies, and in the two cases with the highest levels of neutralization, spike-protein receptor binding domain (RBD)-specific IgG was detected with an in-house assay.

The authors concluded that patients with severe COVID-19 both seroconvert earlier and develop higher concentrations of SARS-CoV-2-specific IgG than patients with mild symptoms. That not all COVID-19 patients develop detectable levels of IgG using two validated commercial methods, even over time, are vital for the interpretation of COVID-19 seroprevalence surveys and estimating the true prevalence in populations. The study was published on October 21, 2020 in the journal PLOS ONE.



New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Vaginitis Test
Allplex Vaginitis Screening Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.